The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.

ABSTRACT:

Background

Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303 trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell lung cancer (NSCLC) patients. Meanwhile, the impact of previous therapy strategies on the efficiency of anlotinib still remains unknown.

Methods

The subgroup of patients in ALTER0303 were analyzed by using Kaplan-Meier estimates, Pearson χ², or Fisher's exact test.

Results

There was no statistical significance on progression-free survival (PFS) and overall survival (OS) among patients in different previous antiangiogenic treatments groups. Patients in the chest radiotherapy (CRT) group had longer median PFS than the non-CRT group (5.93 vs. 4.63 m, P=0.027). Regardless o

SUBMITTER: Wang L 

PROVIDER: S-EPMC6835105 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature